Stay updated on Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial
Sign up to get notified when there's something new on the Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial page.

Latest updates to the Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded detailed bone mineral density (BMD) Z-score change data at weeks 17, 41, 57, and 105 with race/age/gender standardization. Introduced summaries of participant satisfaction and product preference at Weeks 17 and 41, and removed older dated entries (2025-09 and 2025-10-10).SummaryDifference0.4%

- Check21 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check28 days agoChange DetectedRevision: v3.4.3 is now displayed, replacing the previous v3.4.2.SummaryDifference0.0%

- Check57 days agoChange DetectedRevision: v3.4.2 is now shown on the page. The previous funding-status notice and Revision: v3.4.1 have been removed.SummaryDifference0.3%

- Check64 days agoChange DetectedAdded a site-wide notice about government funding and NIH Clinical Center status; updated page revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check71 days agoChange DetectedAdded: Show glossary, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, Revision: v3.4.0. Removed or renamed: Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4.SummaryDifference0.2%

Stay in the know with updates to Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Injectable Cabotegravir vs TDF/FTC in MSM Clinical Trial page.